Related references
Note: Only part of the references are listed.A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity
Veronica Krogstad et al.
DRUG METABOLISM AND DISPOSITION (2020)
Association between low body weight and cytochrome P-450 enzyme activity in patients with anorexia nervosa
Pal Sandvik et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates
Elena Puris et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
CYP450 activities before and after Roux-en-Y gastric bypass: correlation with their intestinal and liver content
Celia Lloret-Linares et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2019)
Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity
Jose Rodriguez-Morato et al.
SCIENTIFIC REPORTS (2019)
Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity
V. Shakhnovich et al.
PEDIATRIC OBESITY (2019)
Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
Laureen A. Lammers et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
Higher chlorzoxazone clearance in obese children compared with nonobese peers
C. Gade et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism
Laureen A. Lammers et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
Sex and body weight are major determinants of venlafaxine pharmacokinetics
Georgios Schoretsanitis et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2018)
Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures
Valentina Shakhnovich et al.
JOURNAL OF PEDIATRICS (2018)
Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults
Anne van Rongen et al.
CLINICAL PHARMACOKINETICS (2018)
Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach
Laureen A. Lammers et al.
CLINICAL PHARMACOKINETICS (2017)
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update
J. K. Hicks et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen
Anne van Rongen et al.
CLINICAL PHARMACOKINETICS (2016)
A short-term high fat diet increases exposure to midazolam and omeprazole in healthy subjects
Roos Achterbergh et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
CYP gene expressions in obesity-associated metabolic syndrome
Suzan Tabur et al.
OBESITY RESEARCH & CLINICAL PRACTICE (2016)
Semiphysiologically Based Pharmacokinetic Model for Midazolam and CYP3A Mediated Metabolite 1-OH-Midazolam in Morbidly Obese and Weight Loss Surgery Patients
M. J. E. Brill et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
Lack of a significant change in caffeine metabolism in underweight children as determined by the caffeine breath test
K. A. Oshikoya et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2015)
Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents
Anne van Rongen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery
Margreke J. Brill et al.
PHARMACEUTICAL RESEARCH (2015)
Proximal Roux-en-Y Gastric Bypass Alters Drug Absorption Pattern But Not Systemic Exposure of CYP3A4 and P-glycoprotein Substrates
Lingtak-Neander Chan et al.
PHARMACOTHERAPY (2015)
Short-Term Fasting Alters Cytochrome P450-Mediated Drug Metabolism in Humans
Laureen A. Lammers et al.
DRUG METABOLISM AND DISPOSITION (2015)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Alcohol Metabolism
Arthur I. Cederbaum
CLINICS IN LIVER DISEASE (2012)
Maternal obesity alters feto-placental cytochrome P4501A1 activity
B. N. DuBois et al.
PLACENTA (2012)
Altered xanthine oxidase and N-acetyltransferase activity in obese children
Manoj S. Chiney et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility
M. Dobrinas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Obesity Affects the Liver - The Link between Adipocytes and Hepatocytes
Alexander Wree et al.
DIGESTION (2011)
Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans
Helena Anna Thorn et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Antidepressant Treatment and Altered CYP2D6 Activity: Are Pharmacokinetic Variations Clinically Relevant?
Inna D'Empaire et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2011)
Overweight, Obesity, and Depression A Systematic Review and Meta-analysis of Longitudinal Studies
Floriana S. Luppino et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Katherine M. Flegal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Effect of a High-Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects
Chirag G. Patel et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
Patrick A. Thompson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis
H. Fukuchi et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease
Craig D. Fisher et al.
DRUG METABOLISM AND DISPOSITION (2009)
Obesity prevalence from a European perspective:: a systematic review
Anne Berghoefer et al.
BMC PUBLIC HEALTH (2008)
Cytochrome P450 and chemical toxicology
F. Peter Guengerich
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Effects of steatosis on drug-metabolizing capability of primary human hepatocytes
M. T. Donato et al.
TOXICOLOGY IN VITRO (2007)
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity
Dhanashri Kolwankar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Complex reactions catalyzed by cytochrome P450 enzymes
Ernre M. Isin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2007)
Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts
M. Teresa Donato et al.
DRUG METABOLISM AND DISPOSITION (2006)
Prevalence of overweight and obesity in the United States, 1999-2004
CL Ogden et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Function of human cytochrome P450s: Characterization of the orphans
FP Guengerich et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Drug therapy - Drug metabolism and variability among patients in drug response
GR Wilkinson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effects of malnutrition on cytochrome P450 1A2 activity in elderly patients
B Hamon-Vilcot et al.
THERAPIE (2004)
Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants
DR Nelson et al.
PHARMACOGENETICS (2004)
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease
MG Emery et al.
HEPATOLOGY (2003)
Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects
J Wójcicki et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2003)
Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions
R Yuan et al.
DRUG METABOLISM AND DISPOSITION (2002)
The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans
PB Danielson
CURRENT DRUG METABOLISM (2002)
Clinical importance of the cytochromes P450
DW Nebert et al.
LANCET (2002)
Effects of obesity on pharmacokinetics - Implications for drug therapy
G Cheymol
CLINICAL PHARMACOKINETICS (2000)
Pharmacokinetics of quinine in obesity
S Viriyayudhakorn et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2000)
Share Paper
